Therapeutic effectiveness of a single vs multiple doses of erythropoietin after experimental myocardial infarction in rats

Cardiovascular Drugs and Therapy

Volumn 20, Issue 4, 2006, Pages 245-251

  Moon, Chanil ^a   Krawczyk, Melissa ^a   Lakatta, Edward G ^a   Talan, Mark I ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Cardiac remodeling; Erythropoietin; Myocardial infarction

Indexed keywords

ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY LIGATION; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DESCENDING AORTA; DRUG DOSE REGIMEN; DRUG EFFICACY; ECHOCARDIOGRAPHY; HEART EJECTION FRACTION; HEART INFARCTION; HEART LEFT VENTRICLE PRESSURE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE REMODELING; HEMATOCRIT; HISTOLOGY; MALE; MORTALITY; MULTIPLE DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE;

ANIMALS; CARDIOTONIC AGENTS; ECHOCARDIOGRAPHY; ERYTHROPOIETIN, RECOMBINANT; HEART VENTRICLES; HEMATOCRIT; MALE; MYOCARDIAL INFARCTION; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR REMODELING;

EID: 33750683636     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-006-0080-z     Document Type: Article

References (33)

1. Erbayraktar S, Yilmaz O, Gokmen N, Brines M. Erythropoietin is a multifunctional tissue-protective cytokine. Curr Hematol Rep 2003;2:465-70.
2. Coleman T, Brines M. Science review: recombinant human erythropoietin in critical illness: a role beyond anemia? Crit Care 2004 Oct;8:337-41.
3. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002 Aug;8:495-505.
4. Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003 Sep 1;59:538-48 (Review).
5. Bogoyevitch MA. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res 2004 Aug 1;63:208-16 (Review).
6. van der Meer P, Voors AA, Lipsic E, van Gilst WH, van Veldhuisen DJ. Erythropoietin in cardiovascular diseases. Eur Heart J 2004 Feb;25:285-91 (Review).
7. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:10526-31.
8. Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG, et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA 2003 Sep 30;100:11612-7.
9. Moon C, Krawczyk M, Paik D, Lakatta EG, Talan MI. Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window. Cardiovasc Drugs Ther 2005 Aug;19(4):243-50.
10. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005;293:90-5 (Review).
11. Genc S, Koroglu TF, Genc K. Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci 2004;22:105-19.
12. Maiese K, Li F, Chong ZZ. Erythropoietin in the brain: can the promise to protect be fulfilled? Trends Pharmacol Sci 2004;25:577-83.
13. Jelkmann W, Wagner K. Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol 2004;83:673-86.
14. Lipsic E, van der Meer P, Voors AA, Westenbrink BD, van den Heuvel AF, de Boer HC, et al. A single bolus of a long-acting erythropoietin analogue Darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 2006;20:135-41.
15. van der Meer P, Voors AA, Lipsic E, Smilde TD, van Gilst WH, van Veldhuisen DJ. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 2004;44:63-7.
16. Henry DH, Bowers P, Romano MT, Provenzano R. Epoetin alfa: clinical evolution of a pleiotropic cytokine. Arch Intern Med 2004;164:262-76.
17. Bogar L, Juricskay I, Kesmarky G, Kenyeres P, Toth K. Erythrocyte transport efficacy of human blood: a rheological point of view. Eur J Clin Investig 2005;35:687-90.
18. Kwaan HC, Wang J. Hyperviscosity in polycythemia vera and other red cell abnormalities. Semin Thromb Hemost 2003;29:451-8.
19. Wiessner C, Allegrini PR, Ekatodramis D, Jewell UR, Stallmach T, Gassmann M. Increased cerebral infarct volumes in polyglobulic mice overexpressing erythropoietin. J Cereb Blood Flow Metab 2001;21:857-64.
20. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck K. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002;64:326-33.
21. Squadrito F, Altavilla D, Squadrito G, Campo GM, Arlotta M, Quartarone C, et al. Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock. Br J Pharmacol 1999;127:482-8.
22. Shingo T, Sorokan ST, Shimazaki T, Weiss S. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 2001;21:9733-43.
23. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003 Aug 15;102(4):1340-6.
24. Ghezzi P, Brines M. Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ 2004 Jul;11 Suppl 1:S37-44.
25. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 2004 Jun;113:1535-49.
26. Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 1999;19:643-51.
27. Sadamoto Y, Igase K, Sakanaka M, Sato K, Otsuka H, Sakaki S, et al. Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun 1998;253:26-32.
28. Siren AL, Knerlich F, Poser W, Gleiter CH, Bruck W, Ehrenreich H. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol 2001;101:271-6.
29. Rodriguez M, Schaper J. Apoptosis: measurement and technical issues. J Mol Cell Cardiol 2005;38:15-20.
30. Zhao W, Lu L, Chen SS, Sun Y. Temporal and spatial characteristics of apoptosis in the infarcted rat heart. Biochem Biophys Res Commun 2004;325:605-11.
31. Feng QZ, Li TD, Wei LX, Qiao X, Yi J, Wang L, et al. Tempero-spatial dissociation between the expression of Fas and apoptosis after coronary occlusion. Mol Pathol 2003;56:362-7.
32. van der Meer, P, Lipsic E, Henning RH, Boddeus K, van der Velden J, Voors AA, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005;46:125-33.
33. Li L, Takemura G, Li Y, Miysata S, Esaki M, Okada H, et al. Preventive effect of erythropoietin on cardiac dysfunction in doxotubicin-induced cardiomyopathy. Circulation 2006;113:535-43.